Specialty medications are used to treat the most severe and complex conditions, such as cancer, multiple sclerosis, and hepatitis. These drugs are far and away the most expensive of all. In fact, by 2023, the median list price for oncology and orphan drugs could exceed $200,000 per member per year. For this reason, for every payer serving any population, managing spending on specialty drugs must be a top priority.
Plans realize up to 9% in cost savings using MedImpact Direct Specialty
Projected spending in US on specialty medications by 2023
Percentage of total spending on specialty for commercial plans